芪参益气滴丸在老年心肌梗死患者中的应用

The Application of Qishen Yiqi Droplet in Elderly Patients with Myocardial Infarction

目的探讨芪参益气滴丸对老年急性心肌梗死患者的影响。方法将高龄心肌梗死患者86例随机分为观察组和对照组,各43例。对照组采用常规药物治疗,观察组在此基础上配合芪参益气滴丸治疗。结果治疗组总有效率为46.51%,对照组为25.58%,两组比较,差异有统计学意义(P<0.05);治疗后两组左室后壁厚度、左心室舒张末内径和左心室射血分数均较治疗前改善(P<0.05),治疗后观察组改善优于对照组(P<0.05)。治疗后两组脑钠肽(BNP)、C反应蛋白(CRP)均较治疗前改善(P<0.05),治疗后观察组改善优于对照组(P<0.05);治疗后两组TC、LDL-C、CRP均较治疗前改善(P<0.05),治疗后观察组改善优于对照组(P<0.05);观察组治疗后6 min步行距离(370.81±17.20)m,显著高于对照组治疗后的(362.17±15.65)m,差异有统计学意义(P<0.05)。观察组与对照组治疗后心力衰竭、室性心律失常、心房颤动、心绞痛等并发症的发生率比较,差异无统计学意义(P>0.05)。结论常规治疗基础上联用芪参益气滴丸能改善高龄心肌梗死患者左心室功能及血脂水平,减少心肌梗死后心衰的发生。

Objective： To explore the clinical effect of Qishen Yiqi Droplet on elderly patients with acute myocardial infarction. Methods： 86 cases of venerable age patients with myocardial infarction were randomly divided into observation group and control group. The control group was treated with conventional drug,while the observation group was given Qishen Yiqi Droplet on this basis. The clinical results of the two groups were observed. The left ventrieular function index, left ventricular wall thickness, left ventricular end-diastolic diameter （LVEDD）, left ventricular ejection fraction （LVEF） before and after the treatment were detected by echocardiography. Results： In the control group,5 cases were markedly improved,6 cases were effective,20 cases were ineffective and 12 cases died. While in the observation group,9 cases were markedly improved,ll cases were effective, 17 cases were ineffective and 6 cases died. The observation group had better clinical efficacy. After treatment,the left ven- tricular wall thickness,left ventricular end-diastolic diameter and left ventricular ejection fraction of the observed group and the control group were improved （P 〈 0.05）. After treatment, the left ventricular wall thickness, left ven- tricular end-diastolic diameter and left ventricular ejection fraction of observation group were respectively （10.74 ± 0.53） mm, （49.59±1.38） mm,and （0.52±0.14）%,significantly lower than （11.03±0.65） mm, （50.27±1.41） mm and （0.46±0.13）% of the control group （P〈0.05）. After treatment,the TC,LDL-C and CRP of the observation group and the control group were all ameliorated （P〈 0.05）. The TC,LDL-C and CRP of the observation group were respectively （5.23±0.31）mmol/L, （2.88±0.30） mmol/L and （58.21±4.17） mg/L,evidently lower than the （5.40±0.36） mmol/L, （3.02±0.31） mmol/L and （60.30±4.24） mg/L of the control group （P〈 0.05）. After treatment, the brain natriuretic peptide and C-reactive protein of the observation group and the control group were both improved （P〈 0.05）. After treatment,the brain natriuretic peptide and C-reactive protein of the observation group were respectively （138.26±21.94） pg/m and （ 10.78±6.13 ） mg/L, distinctly lower than （160.88±27.49） pg/ mL and （14.26±7.04） mg/L of the control group （P〈 0.05）. After treatment,the walking distance in 6 minutes of the observation group was （370.81±17.20） re,obviously longer than （362.17±15.65） m of the, control group（P〈 0.05）. Conclusion： Qishen Yiqi Droplet being combined with conventional treatment can improve senile myocar- dial infarction of left ventrieular function and blood lipid levels,and reduce the occurrence of heart failure after myocardial infarction.